Scholars@Duke

Management of Immunotherapy-Related Toxicities, Version 1.2019.

Publication ,  Journal Article
Thompson, JA; Schneider, BJ; Brahmer, J; Andrews, S; Armand, P; Bhatia, S; Budde, LE; Costa, L; Davies, M; Dunnington, D; Ernstoff, MS ...
Published in: J Natl Compr Canc Netw
March 1, 2019
Published version (DOI) Link to item

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neuro-oncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was designed in general alignment with recommendations published by ASCO and SITC. The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to chimeric antigen receptor T-cell therapy, visit NCCN.org.

Duke Scholars

Christopher Hoimes
Author Christopher Hoimes Medicine, Medical Oncology
Scott Leigh Shofer
Author Scott Leigh Shofer Medicine, Pulmonary, Allergy, and Critical Care Medicine
Momen Mohammed Wahidi
Author Momen Mohammed Wahidi Medicine, Pulmonary, Allergy, and Critical Care Medicine

Published In

J Natl Compr Canc Netw

DOI

10.6004/jnccn.2019.0013

EISSN

1540-1413

Publication Date

March 1, 2019

Volume

17

Issue

3

Start / End Page

255 / 289

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Neoplasms
  • Molecular Targeted Therapy
  • Humans
  • Drug-Related Side Effects and Adverse Reactions
  • Disease Management
  • Antineoplastic Agents, Immunological
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., … Scavone, J. L. (2019). Management of Immunotherapy-Related Toxicities, Version 1.2019. J Natl Compr Canc Netw, 17(3), 255–289. https://doi.org/10.6004/jnccn.2019.0013
Thompson, John A., Bryan J. Schneider, Julie Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, et al. “Management of Immunotherapy-Related Toxicities, Version 1.2019.” J Natl Compr Canc Netw 17, no. 3 (March 1, 2019): 255–89. https://doi.org/10.6004/jnccn.2019.0013.
Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. Management of Immunotherapy-Related Toxicities, Version 1.2019. J Natl Compr Canc Netw. 2019 Mar 1;17(3):255–89.
Thompson, John A., et al. “Management of Immunotherapy-Related Toxicities, Version 1.2019.” J Natl Compr Canc Netw, vol. 17, no. 3, Mar. 2019, pp. 255–89. Pubmed, doi:10.6004/jnccn.2019.0013.
Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Hoffner B, Hoimes CJ, Lacouture M, Locke F, Lunning M, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wahidi M, Wang Y, Johnson-Chilla A, Scavone JL. Management of Immunotherapy-Related Toxicities, Version 1.2019. J Natl Compr Canc Netw. 2019 Mar 1;17(3):255–289.

Published In

J Natl Compr Canc Netw

DOI

10.6004/jnccn.2019.0013

EISSN

1540-1413

Publication Date

March 1, 2019

Volume

17

Issue

3

Start / End Page

255 / 289

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Neoplasms
  • Molecular Targeted Therapy
  • Humans
  • Drug-Related Side Effects and Adverse Reactions
  • Disease Management
  • Antineoplastic Agents, Immunological
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis